Mild cognitive impairment and asymptomatic alzheimer disease subjects: Equivalent β-amyloid and tau loads with divergent cognitive outcomes

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 4, 2014, Pages 295-304

  Iacono, Diego ^a,c   Resnick, Susan M ^b   O'Brien, Richard ^a   Zonderman, Alan B ^b   An, Yang ^b   Pletnikova, Olga ^a   Rudow, Gay ^a   Crain, Barbara ^a   Troncoso, Juan C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c Biomedical Research Institute of New Jersey   (United States)

Author keywords

Alzheimer disease; Immunoreactivity; Neuronal hypertrophy; Preserved cognition; Soluble A amyloid; Tau

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ARTICLE; ASYMPTOMATIC ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEREOLOGY; STRIATE CORTEX; TISSUE SECTION; VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOPSY; BRAIN; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSTMORTEM CHANGES; STEREOTAXIC TECHNIQUES; TAU PROTEINS;

EID: 84897418099     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000052     Document Type: Article

References (41)

1. Tomlinson BE, Blessed G, Roth M. Observations on the brains of nondemented old people. J Neurol Sci 1968;7:331-56
2. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138-44
3. Crystal H, Dickson D, Fuld P, et al. Clinicopathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988;38:1682-87
4. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087-95
5. Troncoso JC, Martin LJ, Dal Forno G, et al. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996;17:365-71
6. Snowdon DA. Aging and Alzheimer's disease: Lessons from the Nun Study. Gerontologist 1997;37:150-56
7. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66:1837-44
8. Riudavets MA, Iacono D, Resnick SM, et al. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 2007;28:1484-92
9. Iacono D, O'Brien R, Resnick SM, et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol 2008;67:578-89
10. Driscoll I, Troncoso J. Asymptomatic Alzheimer's disease: A prodrome or a state of resilience? Curr Alzheimer Res 2011;8:330-35
11. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59
12. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
13. Shock NW, Greulick RC, Andres R, et al. Normal Human Aging: The Baltimore Longitudinal Study of Aging. Washington, DC: US Government Printing Office, 1984.
14. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 2012; 123:1-11
15. Kawas C, Gray S, Brookmeyer R, et al. Age-specific incidence rates of Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology 2000;54:2072-77
16. Gamaldo A, Moghekar A, Kilada S, et al. Effect of a clinical stroke on the risk of dementia in a prospective cohort. Neurology 2006;67:1363-69
17. Troncoso JC, Zonderman AB, Resnick SM, et al. Effect of infarcts on dementia in the Baltimore Longitudinal Study of Aging. Ann Neurol 2008;64:168-76
18. Yamamoto T, Hirano A. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 1986;12:3-9
19. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Third Edition-Revised (DSM-III-R). Washington, DC: American Psychiatric Press, Inc, 1987
21. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-44
22. Howard C. Unbiased Stereology. Three Dimensional Measurement in Microscopy. New York, NY: BIOS Scientific Publishers Limited, 1998
23. Armstrong RA. The interface between Alzheimer's disease, normal aging, and related disorders. Curr Aging Sci 2008;1:122-32
24. Thal DR, Capetillo-Zarate E, Del Tredici K, et al. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006;2006:re1
25. Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predicts cognitive status in Alzheimer's disease. Neurology 2003;60:1495-500
26. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 2012;71:362-81
27. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12
28. Hu NW, Smith IM, Walsh DM, et al. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 2008;131:2414-24
29. Perez-Nievas BG, Stein TD, Tai HC, et al. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain 2013;136:2510-26
30. Codispoti KE, Beason-Held LL, Kraut MA, et al. Longitudinal brain activity changes in asymptomatic Alzheimer's disease. Brain Behavior 2012;2:221-30
31. Stern Y. The concept of cognitive reserve: A catalyst for research. J Clin Exp Neuropsychol 2003;25:589-93
32. Fratiglioni L,Wang HX. Brain reserve hypothesis in dementia. J Alzheimers Dis 2007;12:11-22
33. Head E, Corrada MM, Kahle-Wrobleski K, et al. Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging 2009;30:1125-34
34. Bell KF, Bennett DA, Cuello AC. Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. J Neurosci 2007; 27:10810-17
35. Woodard JL, Grafton ST, Votaw JR, et al. Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease. Neuropsychology 1998;12:491-94
36. Grady CL, McIntosh AR, Beig S, et al. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci 2003;23:986-93
37. Buckner RL. Memory and executive function in aging and AD: Multiple factors that cause decline and reserve factors that compensate. Neuron 2004;44:195-208
38. Prvulovic D, Van de Ven V, Sack AT, et al. Functional activation imaging in aging and dementia. Psychiatry Res 2005;140:97-113
39. Dickerson BC, Salat DH, Greve DN, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005;65:404-11
40. Tolboom N, van der Flier WM, Yaqub M, et al. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurol 2009;73:2079-85
41. Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar beta-Amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011;68:232-40